NDAINJECTIONINJECTABLE
Approved
Jun 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
5/8 — Partial
CAVERJECT IMPULSE (alprostadil) by Pfizer is prostaglandin receptor agonists [moa]. Approved for peripheral arterial occlusive disease, erectile dysfunction. First approved in 2002.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CAVERJECT IMPULSE (alprostadil) is a prostaglandin analog administered via injection that works as a prostaglandin receptor agonist to induce vasodilation. It is indicated for erectile dysfunction and peripheral arterial occlusive disease, expanding vascular access and tissue perfusion through direct smooth muscle relaxation.
LOE Approaching
With LOE approaching, the CAVERJECT IMPULSE commercial team is transitioning toward defensive strategy and may be consolidating focus on niche patient populations.
Mechanism of Action
Prostaglandin Receptor Agonists
Pharmacologic Class:
Prostaglandin Analog
Indications (2)
Clinical Trials (3)
Alprostadil in Maculopathy Study (AIMS)
Started Jul 2006
37 enrolled
Macular Degeneration
Topical Alprostadil for Female Sexual Arousal Disorder
Started Sep 2004
300 enrolled
Sexual Dysfunction, Physiological
Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV
Started Mar 2004
840 enrolled
Peripheral Arterial Occlusive Disease
Worked on CAVERJECT IMPULSE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.